
## Andrew Robert John Mitchell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4974786/publications.pdf Version: 2024-02-01



Andrew Robert John

#	Article	IF	CITATIONS
1	Virtual reality device to improve the tolerability of lumbar puncture. BMJ Neurology Open, 2022, 4, e000276.	1.6	1
2	Turning out the lights: the importance of digital health resilience. European Heart Journal Digital Health, 2021, 2, 165-166.	1.7	0
3	Virtual reality as a therapy adjunct during emergency pericardiocentesis. European Heart Journal - Case Reports, 2020, 4, 1-1.	0.6	1
4	A study to assess a novel automated electrocardiogram technology in screening for atrial fibrillation. PACE - Pacing and Clinical Electrophysiology, 2019, 42, 1383-1389.	1.2	7
5	Delayed presentation of right ventricular lead perforation following defibrillator implantation: a case report. European Heart Journal - Case Reports, 2019, 3, ytz121.	0.6	2
6	Can the NHS be a learning healthcare system in the age of digital technology?. BMJ Evidence-Based Medicine, 2018, 23, 161-165.	3.5	6
7	Biomarker Assays for Personalised Stroke Risk Assessment in Atrial Fibrillation. Cardiovascular & Hematological Disorders Drug Targets, 2017, 17, 58-63.	0.7	4
8	Permanent catheter drainage system for palliation of diureticâ€resistant cardiac ascites. ESC Heart Failure, 2016, 3, 60-62.	3.1	7
9	Is there a role for a local inpatient CT coronary angiography service in selected patients with acute coronary syndrome? A cohort analysis of inpatient tertiary centre referrals for invasive coronary angiography. Open Heart, 2016, 3, e000389.	2.3	4
10	Living with the handheld ECG. BMJ Innovations, 2015, 1, 46-48.	1.7	10
11	Atrial Fibrillation – New Frontiers in Anticoagulation. Cardiovascular & Hematological Disorders Drug Targets, 2014, 14, 45-49.	0.7	0
12	Digoxin — Time to take the gloves off?. International Journal of Cardiology, 2013, 164, 365-367.	1.7	12
13	Deconditioning the athletic heart. BMJ Case Reports, 2013, 2013, bcr2013200556-bcr2013200556.	0.5	1
14	Early aeromedical transfer after acute coronary syndromes. Emergency Medicine Journal, 2011, 28, 325-327.	1.0	4
15	Coronary Calcium Screening. New England Journal of Medicine, 2009, 361, 2490-2492.	27.0	1
16	Intracardiac Echocardiography for Patent Foramen Ovale Closure: Justification of Routine Use. JACC: Cardiovascular Interventions, 2009, 2, 369.	2.9	9
17	ls rate more important than rhythm in treating atrial fibrillation? No. BMJ: British Medical Journal, 2009, 339, b3174-b3174.	2.3	5
18	Atrial septal endocarditis. European Journal of Echocardiography, 2007, 8, 48-49.	2.3	6

Andrew Robert John

#	Article	IF	CITATIONS
19	Intracardiac echocardiography to guide myocardial biopsy of a primary cardiac tumour. European Journal of Echocardiography, 2007, 8, 505-506.	2.3	12
20	DC cardioversion of persistent atrial fibrillation: A comparison of two protocols. International Journal of Cardiology, 2007, 114, 16-21.	1.7	25
21	Patent Foramen Ovale and the Risk of Cryptogenic Stroke. Journal of the American College of Cardiology, 2006, 48, 1913-1914.	2.8	2
22	Percutaneous closure of an atrial septal defect in a patient with congenitally corrected transposition. International Journal of Cardiology, 2006, 112, e76-e77.	1.7	1
23	Pacemaker implantation in a patient with paroxysmal atrial fibrillation and left pneumonectomy. International Journal of Cardiology, 2006, 112, e81-e82.	1.7	Ο
24	Cardiac changes in systemic amyloidosis: Visualisation by magnetic resonance imaging. International Journal of Cardiology, 2006, 113, E21-E23.	1.7	30
25	To the Editor:. Journal of Cardiovascular Electrophysiology, 2006, 17, E1-E1.	1.7	3
26	Ventricular septal rupture following abciximab infusion. European Journal of Echocardiography, 2006, 9, 60-2.	2.3	5
27	Percutaneous closure of an iatrogenic atrial septal defect. European Journal of Echocardiography, 2006, 9, 294-5.	2.3	4
28	Pharmacological Management of No Reflow During Percutaneous Coronary Intervention. Current Vascular Pharmacology, 2006, 4, 95-100.	1.7	15
29	Changes in Intrathoracic Impedance from a Pneumothorax: Insights from an Implanted Monitoring System. PACE - Pacing and Clinical Electrophysiology, 2005, 28, 1109-1111.	1.2	8
30	Flecainide overdose – support using an intra-aortic balloon pump. BMC Emergency Medicine, 2005, 5, 10.	1.9	17
31	Left Ventricular Pseudoaneurysm and Rupture After Limited Myocardial Infarction. Journal of the American Society of Echocardiography, 2005, 18, 980.e1-980.e4.	2.8	5
32	Transthoracic diagnosis of left atrial appendage myxoma by real-time 3-dimensional echocardiography. Journal of the American Society of Echocardiography, 2005, 18, 192-193.	2.8	4
33	Safety of contrast dobutamine stress echocardiography: A single center experience. Journal of the American Society of Echocardiography, 2005, 18, 163-167.	2.8	44
34	Myocardial injury, neurohormonal activation and inflammation after internal atrial defibrillation. International Journal of Cardiology, 2005, 103, 67-72.	1.7	7
35	Percutaneous treatment of simultaneous aortic dissection and pericardial tamponade during coronary intervention. International Journal of Cardiology, 2005, 105, 104-107.	1.7	14
36	Non-Pharmacological Methods of Maintaining Sinus Rhythm. Circulation, 2004, 110, e61; author reply 61.	1.6	5

Andrew Robert John

#	Article	IF	CITATIONS
37	How do atrial pacing algorithms prevent atrial arrhythmias?. Europace, 2004, 6, 351-362.	1.7	33
38	The Circadian Variation of Atrial Defibrillation Thresholds. Journal of Interventional Cardiac Electrophysiology, 2004, 10, 79-83.	1.3	2
39	Echocardiographic assessment and percutaneous closure of multiple atrial septal defects. Cardiovascular Ultrasound, 2004, 2, 9.	1.6	14
40	Improving the acceptability of the atrial defibrillator for the treatment of persistent atrial fibrillation: the atrial defibrillator sedation assessment study (ADSAS). International Journal of Cardiology, 2004, 96, 141-145.	1.7	16
41	Long-term care of the patient with the atrial defibrillator. American Heart Journal, 2004, 147, 210-217.	2.7	11
42	Does Rapid Atrial Pacing Terminate Atrial Fibrillation? A Comparison of Laboratory and Device Termination Studies. Journal of Interventional Cardiac Electrophysiology, 2003, 7, 352-354.	1.0	2
43	Psychosocial Aspects of Patientâ€Activated Atrial Defibrillation. Journal of Cardiovascular Electrophysiology, 2003, 14, 812-816.	1.7	13
44	Circadian variation of arrhythmia onset patterns in patients with persistent atrial fibrillation. American Heart Journal, 2003, 146, 902-907.	2.7	46
45	Echocardiographic changes and predictors of arrhythmia recurrence after long-term use of the atrial defibrillator. International Journal of Cardiology, 2003, 89, 25-31.	1.7	6
46	'The patient takes charge' — long term use of the atrial defibrillator. European Heart Journal, 2003, 24, 2075-2076.	2.2	4
47	Mobile phones in hospitals. BMJ: British Medical Journal, 2003, 326, 460-461.	2.3	41
48	Reversal of tachycardiomyopathy by the atrial defibrillator. European Journal of Heart Failure, 2002, 4, 485-488.	7.1	6
49	Atrial fibrillation in the new millenniumthe role of pacemaker and defibrillator therapy. Medical Science Monitor, 2002, 8, RA233-9.	1.1	1
50	The Era of Immersive Health Technology. European Medical Journal Innovations, 0, , 40-47.	2.0	4